The London Clinic is the UK’s most famed unbiased, non-public hospital, established 1932.
The London Backbone Clinic is first specialist spinal unit established in England, 1997.
The London Clinic shall be Aclarion’s first buyer in London.
BROOMFIELD, CO, Might 30, 2023 (GLOBE NEWSWIRE) — through NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare know-how firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians establish the placement of continual low again ache, introduced right this moment their business settlement with the celebrated London Clinic, London, UK. The London Clinic is likely one of the UK’s largest and most famed unbiased hospitals. Based mostly within the coronary heart of London’s medical district, the Clinic has a heritage of investing within the newest applied sciences and offering distinctive medical care by means of state-of-the-art services.
“With a give attention to offering the perfect healthcare outcomes, The London Clinic is a perfect buyer for Aclarion as the corporate works to ship the Nociscan resolution to physicians and sufferers around the globe,” stated John Sutcliffe MD, Neurosurgeon and Founding father of London Backbone Clinic. “The engagement with Aclarion will enable London Backbone Clinic to proceed providing the high-quality care our sufferers have come to anticipate. Sufferers want a cautious evaluation, analysis, and understanding of the completely different remedy choices accessible to them. Aclarion’s progressive Nociscan resolution will allow us to objectively assess biomarkers related to low again ache and improve the precision of every analysis.”
Power low again ache (cLBP) is a worldwide healthcare drawback, with roughly 266 million folks worldwide affected by degenerative spine illness and low again ache. Low again ache has been estimated to have an effect on as much as one third of the UK grownup inhabitants annually. The London Backbone Clinic launched in 1997 as the primary non-public specialist spinal unit in England. A multidisciplinary spine heart of excellence, it grew to become a part of The London Clinic in 2021 to higher serve sufferers.
“The UK is a crucial international market, and London particularly represents the big, dynamic nature of subtle healthcare,” stated Ryan Bond, Chief Technique Officer at Aclarion. “We’re happy to have interaction with The London Clinic and London Backbone Clinic, empowering these main organizations with our progressive know-how. Along with every day medical use, we additionally plan to additional our dedication to main with overwhelming medical proof by means of future post-market trials with these exemplary London-based clients.”
For extra details about The London Clinic, please go to: www.thelondonclinic.co.uk
For extra details about the London Backbone Clinic, please go to: www.londonspineclinic.com
About Aclarion, Inc.
Aclarion is a healthcare know-how firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing methods, biomarkers, and augmented intelligence algorithms to optimize medical remedies. The Firm is first addressing the continual low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By way of a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing methods extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers crucial insights into the placement of a affected person’s low again ache, giving physicians readability to optimize remedy methods. For extra data, please go to www.aclarion.com.
Ahead Trying Statements
This press launch comprises forward-looking statements inside the that means of the Non-public Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Alternate Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic information, resembling “anticipates,” “believes” and “expects” or comparable expressions, are forward-looking statements. These forward-looking statements are primarily based on the present plans and expectations of administration and are topic to various uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra absolutely in our filings with the Securities and Alternate Fee. Readers are inspired to evaluation the part titled “Danger Elements” within the Firm’s Annual Report on Type 10-Ok for the yr ended December 31, 2022, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Alternate Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Disclosure
The knowledge said above was ready by Aclarion and displays solely the opinion of Aclarion. Nothing on this assertion shall be construed to suggest any assist or endorsement of Aclarion or any of its merchandise by The London Clinic. Mr. Sutcliffe is a shareholder in Aclarion.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
Discussion about this post